Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
Background: Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi, formulated for intravenous (IV) and oral administration. Methods: This global, multicenter, non-comparative study evaluated the safety and efficacy of fosmanogepix for first-line treatment of candidaemia in non-neutropenic adults. Participants with candidaemia, defined as a positive blood culture for Candida spp. within 96 h prior to study entry, with ≤2 days of prior systemic antifungals, were eligible. Participants received fosmanogepix for 14 days: 1000 mg IV twice daily on Day 1, followed by maintenance 600 mg IV once daily, and optional switch to 700 mg orally once daily from Day 4. Eligible participants who received at least one dose of fosmanogepix and had confirmed diagnosis of candidaemia (<96 h of treatment start) composed the modified intent-to-treat (mITT) population. Primary efficacy endpoint was treatment success at the end of study treatment (EOST) as determined by the Data Review Committee. Success was defined as clearance of Candida from blood cultures with no additional antifungal treatment and survival at the EOST. Results: Treatment success was 80% (16/20, mITT; EOST) and Day 30 survival was 85% (17/20; 3 deaths unrelated to fosmanogepix). Ten of 21 (48%) were switched to oral fosmanogepix. Fosmanogepix was well tolerated with no treatment-related serious adverse events/discontinuations. Fosmanogepix had potent in vitro activity against baseline isolates of Candida spp. (MICrange: CLSI, 0.002–0.03 mg/L). Conclusions: Results from this single-arm Phase 2 trial suggest that fosmanogepix may be a safe, well-tolerated, and efficacious treatment for non-neutropenic patients with candidaemia, including those with renal impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, data from a Phase 2 study of patients with candidemia with C. albicans, C. glabrata, C. parapsilosis, and/or C. dubliniensis demonstrated successful outcomes in 16/20 patients without significant adverse events.162”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [162]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationPappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Self-citationAnidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
Self-citationAndes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
Self-citationMicafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Self-citationIncidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451
Candida auris: an Emerging Fungal Pathogen
Spivak, E. S., & Hanson, K. E. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01588-17 · Cited by 393
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
Research works printed but not linked: 1
- CLSI, 2017, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts—Fourth Edition: M27
Cited by
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 185
Self-citationEpidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Self-citationGiannella, M., Lanternier, F., Dellière, S., Groll, A. H., Mueller, N. J., Alastruey‐Izquierdo, A., & Slavin, M. A. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.08.006 · Cited by 106
New treatment options for critically important WHO fungal priority pathogens
Kriegl, L., Egger, M., Boyer, J., Hoenigl, M., & Krause, R. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.03.006 · Cited by 105
Vazquez, J. A., Pappas, P. G., Boffard, K., Paruk, F., Bien, P. A., Tawadrous, M., Ople, E., Wedel, P., Oborska, I., & Hodges, M. R. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01419-22 · Cited by 92
Self-citationTreatment of Invasive Aspergillosis: How It’s Going, Where It’s Heading
Boyer, J., Feys, S., Zsifkovits, I., Hoenigl, M., & Egger, M. (2023) · Mycopathologia · doi:10.1007/s11046-023-00727-z · Cited by 77
Jaggi, T. K., Agarwal, R., Tiew, P. Y., Shah, A., Lydon, E., Hage, C. A., WATERER, G. W., Langelier, C., Delhaès, L., & Chotirmall, S. H. (2024) · European Respiratory Journal · doi:10.1183/13993003.00803-2024 · Cited by 63
Hodges, M. R., Tawadrous, M., Cornely, O. A., Thompson, G. R., Slavin, M. A., Maertens, J. A., Dadwal, S., Rahav, G., Hazel, S., Almas, M., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf185 · Cited by 51
Self-citationCandidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment
Cabrera-Guerrero, J. P., García-Salazar, E., Hernández‐Silva, G., Herrera, A. C., Martínez-Herrera, E. O., Pinto‐Almazán, R., León, M. G. F.-D., & Castro-Fuentes, C. A. (2025) · Pathogens · doi:10.3390/pathogens14080806 · Cited by 52
A synthetic peptide mimic kills Candida albicans and synergistically prevents infection
Schaefer, S., Vij, R., Sprague, J. L., Austermeier, S., Dinh, H., Judzewitsch, P. R., Müller‐Loennies, S., Silva, T. L., Seemann, E. A., Qualmann, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50491-x · Cited by 45
New antifungal strategies and drug development against WHO critical priority fungal pathogens
Li, Y., Liu, Y., Jiang, Y., Yang, Y., Ni, W., Zhang, W., & Tan, L. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1662442 · Cited by 53
Almajid, A., Bazroon, A. A., Al-Awami, H., Albarbari, H., Alqahtani, I., Almutairi, R., Alsuwayj, A., Alahmadi, F., Aljawad, J., Alnimer, R., et al. (2024) · Cureus · doi:10.7759/cureus.59210 · Cited by 50
The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives
de Souza, C. M., Bezerra, B. T., Mellon, D. A., & de Oliveira, H. C. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100341 · Cited by 53
Invasive Candidiasis in the Intensive Care Unit: Where Are We Now?
Vázquez, J. A., Whitaker, L., & Zubovskaia, A. (2025) · Journal of Fungi · doi:10.3390/jof11040258 · Cited by 32
Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management
Akinosoglou, K., Livieratos, A., Asimos, K., Donders, F., & Donders, G. G. G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121555 · Cited by 38
Pfaller, M. A., Huband, M. D., Bien, P. A., Carvalhaes, C. G., Klauer, A. L., & Castanheira, M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01132-23 · Cited by 27
Self-citationRecent Advances in the Development of Antifungal Agents: Beyond Azoles, Polyenes, and Echinocandins
Saini, V., Safwan, S. M., Mehta, D., Das, E. E., & Bajaj, A. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00828 · Cited by 25
Invasive candidiasis in intensive care medicine: shaping the future of diagnosis and therapy
Martín‐Loeches, I., Cornely, O. A., Denning, D. W., Guinea, J., Bassetti, M., Maertens, J. A., Hoenigl, M., Kanj, S. S., Slavin, M. A., Ostrosky-Zeichner, L. L., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08151-1 · Cited by 23
What do We Know about Cryptic Aspergillosis?
Geremia, N., Giovagnorio, F., Colpani, A., VITO, A. D., Caruana, G., Meloni, M. C., Madeddu, G., Panese, S., & Parisi, S. G. (2024) · Microorganisms · doi:10.3390/microorganisms12050886 · Cited by 21
Espinel‐Ingroff, A., & Wiederhold, N. P. (2024) · Journal of Fungi · doi:10.3390/jof10050362 · Cited by 19
Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris
Arumugam, G., Muthuselvam, M., de Lima, P. M. N., Rajendran, R., & Junqueira, J. C. (2024) · Journal of Fungi · doi:10.3390/jof10060408 · Cited by 22
Combatting Fungal Infections: Advances in Antifungal Polymeric Nanomaterials
Schaefer, S., Corrigan, N. A., Brunke, S., Lenardon, M. D., & Boyer, C. A. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00866 · Cited by 19
Antifungal Therapies for Aspergillus spp.: Present and Future
Eschenauer, G. A. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1776776 · Cited by 15
Resilience in Resistance: The Role of Cell Wall Integrity in Multidrug-Resistant Candida
Banda-Flores, I. A., Torres‐Tirado, D., Mora-Montes, H. M., Pérez‐Flores, G., & Pérez-García, L. A. (2025) · Journal of Fungi · doi:10.3390/jof11040271 · Cited by 17
Hirayama, T., Miyazaki, T., Tanaka, R., Kitahori, N., Yoshida, M., Takeda, K., Ide, S., Iwanaga, N., Tashiro, M., Takazono, T., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01508-24 · Cited by 15
Hodges, M. R., Hazel, S., Kramer, W. G., van Hoogdalem, E., van Marle, S., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01455-23 · Cited by 13
Self-citationBarker, K. S., Patterson, H. P., Morschhäuser, J., Cuomo, C. A., Wiederhold, N. P., & Rogers, P. D. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00680-25 · Cited by 14
Antifungal pipeline: Is there light at the end of the tunnel?
Schinas, G., Spernovasilis, N. A., & Akinosoglou, K. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i16.2686 · Cited by 13
Nickels, T. J., Gale, A. N., Harrington, A. A., Timp, W., & Cunningham, K. W. (2024) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkae173 · Cited by 12
Squitieri, D., Rizzo, S., Torelli, R., Mariotti, M., Sanguinetti, M., Cacaci, M., & Bugli, F. (2025) · Pharmaceuticals · doi:10.3390/ph19010008 · Cited by 12
Hodges, M. R., van Marle, S., Kramer, W. G., Ople, E., Tawadrous, M., & Jakate, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01650-23 · Cited by 11
Self-citationAn update on newer antifungals
Akinosoglou, K., Papageorgiou, D., Gogos, C. A., & Dimοpoulos, G. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2461566 · Cited by 11
Current Antifungals and the Developing Pipeline
Johnson, M. D., & Moore, W. J. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.01.001 · Cited by 12
Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
August, B., & Kale-Pradhan, P. B. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2926 · Cited by 11
New pharmacotherapeutic strategies for drug-resistant Candida infections: a review
Raposa, J., & Vázquez, J. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2433605 · Cited by 12
Chen, Y., Dhillon, S., Adomakoh, N., & Roberts, J. A. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2539427 · Cited by 9
Spectrum and management of rare Candida /yeast infections in Kuwait in the Middle East
Ahmad, S., Asadzadeh, M., Al‐Sweih, N., & Khan, Z. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241263733 · Cited by 8
Invasive Candidiasis in Critically Ill Patients
Pérez, M. A., Hoffmann, W. J., Pérez, J. C., & Adelman, M. W. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.12.020 · Cited by 7
Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program
Cohen, S. H., Allyn, P. R., Chow, F. C., Rathe, J., Nanayakkara, D. D., Hutfles, G., Vijayan, T., Smith, E. A., Saling, C. F., Ilges, D., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag271 · Cited by 6
Self-citationNew Perspectives on Antimicrobial Agents: Fosmanogepix
Lamoth, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-26 · Cited by 6
New and emerging drugs for the treatment of invasive fungal infections
Maves, R. C., & Fowler, M. N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2568547 · Cited by 5
Chastain, D. B., Anderson, D. T., Eudy, J., Henao‐Martínez, A. F., & Cluck, D. B. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag055 · Cited by 5
Timotheous, R., Naz, H., Arif, U., Dar, M. T., Sarwar, M. F., Awan, M. F., Ali, S., & Rab, S. O. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-024-10400-5 · Cited by 5
Current and emerging therapies for fungal biofilms and systemic infections
Elgammal, Y., Martinez, R. I. G., Requejo, A., & Martinez, L. R. (2025) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2570185 · Cited by 4
Komath, S. S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107444 · Cited by 4
Garnham, M. D., Agüero, F., Ramírez, J. C., Agüero, F., & Salas‐Sarduy, E. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00900 · Cited by 3
Douglas, A. P., & Slavin, M. A. (2026) · Transplant Infectious Disease · doi:10.1111/tid.70197 · Cited by 3
Usage of Antifungal Agents in Pediatric Patients Versus Adults: Knowledge and Gaps
Kourti, M., & Roilides, E. (2024) · Mycopathologia · doi:10.1007/s11046-024-00896-5 · Cited by 3
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 3
Wiederhold, N. P., Patterson, H. P., Sanders, C. J., & Cañete-Gibas, C. F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-26 · Cited by 2
Invasive Candidiasis Due to Candida albicans and Its Treatment
Acosta, J. A. H., León, M. F. C., Jarrín, N. D. C. Q., Acosta, P. V. S., Herrera, M. V. V., Ruiz, S. P. C., Espinoza, B. C. G., Guala, W. B. I., Macías, J. E. B., & Estrella, A. G. M. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004148 · Cited by 3
Exploring New Antifungal Agents for the Treatment of Candida Infections in the Era of Resistance
Bhatol, J., Dwivedi, S., Jain, V. K., Sisodiya, N., & Darwhekar, G. N. (2025) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3448 · Cited by 1
Ji, J., Xu, W., & Chen, Y. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1796121 · Cited by 1
Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1
Colombo, A. L., Magri, M. M. C., Carlesse, F. A. D. M. C., Falci, D. R., Garnica, M., Santos, D. W. D. C. L., Queiroz‐Telles, F., & Pasqualotto, A. C. (2026) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2026.105946 · Cited by 2
Management of Chronic Pulmonary Aspergillosis
Bongomin, F., Bromley, M., & Armstrong-James, D. P. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-76524-7_17
Research and Development of Antifungal Drugs
陈, 庆. (2026) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2026.161014
Nuevas opciones terapéuticas en el manejo de candidemia y candidiasis invasiva
Zavaleta, E. P. C., Linares-Armas, F. L., Maquera-Afaray, J., & Paz-Paz, J. (2025) · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo · doi:10.35434/rcmhnaaa.2025.182.2816
Al‐Obaidi, M. M., Nematollahi, S., Hayes, J. F., & Nix, D. E. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2651278
Anti-infective therapy and novel treatment options for coccidioidomycosis
Kuo, A. P., Hamdan, S., Donnelley, M., & Thompson, G. R. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2693682 · Cited by 1
Self-citationEmerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives
Al‐Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Al-Zoubi, Y. R., Shkoor, M., Alkharraz, L. M., Agouni, A., & Al-Jabiry, A. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119194
Novel antifungal agents for treating endemic mycoses: hope on the horizon?
Bahr, N. C., Pasqualotto, A. C., & Thompson, G. R. (2026) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001225 · Cited by 1
Self-citationNovel Therapeutics and Antifungal Agents
Anil, A., Chakrabarti, A., & Rudramurthy, S. M. (2026) · Microbiology & infectious diseases : · doi:10.33590/microbiolinfectdisam/462kwc92
Martín‐Loeches, I., & Yu, Y. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2726965
Bratosin, F., Bogdan, I. G., & Pescariu, S. A. (2026) · Journal of Fungi · doi:10.3390/jof12100733
Zhu, G., Zheng, N., Zhai, P., & Mou, Y. (2026) · Biomedical Reports · doi:10.3892/br.2026.2204
Taman, M., Teshome, A., Porto, C. M., Dailey, J. M., Tung, G., Burns, R. H., Punsoni, M., Farmakiotis, D., & Malik, A. N. (2026) · World Neurosurgery · doi:10.1016/j.wneu.2026.125354
The Antifungal Pipeline: New and Future Antifungals
Hendrix, C., Blum, S., Zuniga-Moya, J. C., Spec, A., & Rauseo, A. M. (2026) · Current Clinical Microbiology Reports · doi:10.1007/s40588-026-00280-5
In vitro activity of manogepix against Candida spp. displaying elevated echinocandin MIC results
Winkler, M., Kimbrough, J. H., Edeker, S., Klauer, A. L., Karr, M. H., Rhomberg, P. R., & Castanheira, M. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00859-26
Fosmanogepix-induced agranulocytosis
Lortholary, O., Blez, D., Chantelot, L., Desnos‐Ollivier, M., Rouzaud, C., Dannaoui, É., & Lanternier, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00605-26
Metadata
- Authors
- Pappas, P. G., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., Mccarty, T., Thompson, G. R., Schlamm, H., Bien, P. A., Barbat, S. H., Wedel, P., Oborska, I., Tawadrous, M., & Hodges, M. R.
- Affiliations
- University of Alabama at Birmingham (US)
- Division of Infectious Disease, Department of Medicine, Medical College of Georgia/Augusta University , Augusta, GA , USA
- Rambam Health Care Campus (IL)
- Tel Aviv University (IL)
- Department of Internal Medicine, Institut Jules Bordet , Brussels , Belgium
- CHU Dinant Godinne UCL Namur (BE)
- Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University , Tel Aviv , Israel
- Vall d'Hebron Institut de Recerca (ES)
- University of California Davis Medical Center (US)
- Amplyx Pharmaceuticals (United States) (US)
- Pfizer (United States) (US)
- Corresponding author
- Tawadrous, Margaret
- ORCID
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-08-19
- Volume
- 78
- Issue
- 10
- Pages
- 2471-2480
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC10545531
- OpenAlex
- W4386002220
- Semantic Scholar
- 58980759fdafaac48d6729774c61a6326d556a22
- Cited by
- 65
- References
- 36
- Citations by year
- 2026: 19 · 2025: 19 · 2024: 25 · 2023: 2
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Digital Access to Libraries (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Funders
- Amplyx
- Pfizer Inc
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- fosmanogepix, candidemia, Candida, antifungal agents, non-neutropenic patients, treatment success, survival, renal dysfunction, multidrug-resistant fungi, safety and tolerability
- MeSH terms
- Adult, Antifungal Agents, Candida, Fungi, Humans, Treatment Outcome, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.